Sun Pharma Joins White House Ceremony for U.S. Medicines Pricing Commitments
Sun Pharma committed to extending Most Favored Nation (MFN) pricing to state Medicaid programs and for future innovative medicine launches. The company also secured a delay in Section 232 tariffs on innovative pharmaceutical products for over two years as part of agreements announced at a White House ceremony on September 1, 2026.
The commitments regarding pricing and tariff delays are significant for the company's U.S. operations and revenue, impacting its market position and future growth strategy.
The announcement highlights Sun Pharma's commitment to affordable medicines and its investment in the U.S. market, which are positive developments for the company and patients.
Sun Pharmaceutical Industries Limited (Sun Pharma) participated in a White House ceremony on September 1, 2026, alongside other pharmaceutical companies, to announce agreements with the U.S. government focused on enhancing access to affordable medicines for American patients.
As part of its commitment, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programs and for future innovative medicine launches. The agreement also acknowledges Sun Pharma's investment in the U.S. market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years, with further terms remaining confidential.
Rick Ascroft, North America CEO of Sun Pharma, stated that the company's mission is to provide quality medicines across a patient's treatment journey. He highlighted the U.S. as a key area for investment and expansion in clinical development, sales, marketing, and manufacturing, expressing pride in contributing to the medicines millions of American patients rely on.
The U.S. is Sun Pharma's largest market for innovative medicines, contributing approximately 27% of the company's global revenue. This commitment was further emphasized by Sun Pharma's earlier agreement to acquire Organon & Co. at an enterprise value of $11.75 billion.
Sun Pharma, a leading global pharmaceutical company, has a significant presence in the U.S., ranking second by prescriptions in dermatology and expanding in areas like immunology, cutaneous oncology, and ophthalmology, in addition to its consumer health products and generics business.
A plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.